James Harvey Carter Jr.

Investigator on the following Studies/Protocols:

Study Title: "A multicenter Phase II Study of TP-38 in those patients with glioblastoma multiforme who have recurred or progressed after previous resection and radiation therapy and are scheduled for gross total resection"

Study Title: "A Phase II Trial of Gliodal PWS06-Benzylquanine for patients with recurrent glioblastoma multiforme"

Study Title: "T-regs in blood underlying tumor escape"

Study Title: "Specimen collection in patients treated up front for malignant astrocytoma"

Study Title: A Complementary Trial of an Immunotherapy Vaccine Against Tumor-Specific EGFRvIII

Study Title: Specimen Collection on Patients Treated Up Front for Malignant Astrocytomas

Study Title: Phase III Randomized Evaluation of Convection Enhanced Delivery of IL13-PE38QQR Compared to Gliadel Wafer with Survival Endpoint in Glioblastoma Multiforme Patients At First Recurrence

Study Title: Phase II Study of 131I-Labeled Anti-tenascin Murine Monoclonal Antibody 81C6 (mu81C6) Administered to Deliver a Targeted Radiation Boost Dose of 44Gy to the Surgically Created Cystic Resection Cavity Perimeter Followed by Conventional External Beam Radiotherapy and Temozolomide for Patients with Newly Diagnosed Glioblastoma Multiforme